2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
US-12522594-B2 · Jan 13, 2026 · US
This page is not indexed by search engines while we improve data quality.
Bader Benjamin patents
Bader Benjamin is listed as an inventor on 64 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Bader Benjamin |
| Total patents | 64 |
| First publication | Jul 9, 2015 |
| Latest publication | Jan 13, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Substituted aminoquinolones as dgkalpha inhibitors for immune activation
US-12478621-B2 · Nov 25, 2025 · US
Fused pyrimidines as kras inhibitors
US-2025154170-A1 · May 15, 2025 · US
2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
US-2024294505-A1 · Sep 5, 2024 · US
Phosphorus derivatives as novel sos1 inhibitors
US-2024247015-A1 · Jul 25, 2024 · US
Substituted aminoquinolones as DGKalpha inhibitors for immune activation
US-11998539-B2 · Jun 4, 2024 · US
Substituted aminothiazoles as DGKzeta inhibitors for immune activation
US-11964953-B2 · Apr 23, 2024 · US
2-Methyl-Quinazolines
US-2024083857-A1 · Mar 14, 2024 · US
Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors
US-2023357239-A1 · Nov 9, 2023 · US
2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
US-11795164-B2 · Oct 24, 2023 · US
Recent patents
Latest publications not already listed above.
Substituted aminothiazoles as dgkzeta inhibitors for immune activation
US-2023167103-A1 · Jun 1, 2023 · US
Substituted aminothiazoles as dgkzeta inhibitors for immune activation
US-2023167078-A1 · Jun 1, 2023 · US
Substituted aminothiazoles as dgkzeta inhibitors for immune activation
US-2023139936-A1 · May 4, 2023 · US
2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
US-2023121195-A1 · Apr 20, 2023 · US
[1,2,4]triazolo[1,5-c]quinazolin-5-amines
US-2023113037-A1 · Apr 13, 2023 · US
3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
US-11591311-B2 · Feb 28, 2023 · US
2-methyl-aza-quinazolines
US-2023029385-A1 · Jan 26, 2023 · US
2-(morpholin-4-yl)-1,7-naphthyridines
US-11529356-B2 · Dec 20, 2022 · US
2-phenylpyrimidine-4-carboxamides as AHR inhibitors
US-11524944-B2 · Dec 13, 2022 · US
Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
US-11459312-B2 · Oct 4, 2022 · US
2-methyl-aza-quinazolines
US-2022274979-A1 · Sep 1, 2022 · US
2-methyl-quinazolines
US-2022235013-A1 · Jul 28, 2022 · US
Identification and use of kras inhibitors
US-2022227729-A1 · Jul 21, 2022 · US
2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists
US-11304946-B2 · Apr 19, 2022 · US
3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
US-11040035-B2 · Jun 22, 2021 · US
4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders
US-2021047297-A1 · Feb 18, 2021 · US
Heteroarylbenzimidazole compounds
US-10894784-B2 · Jan 19, 2021 · US
2-(morpholin-4-yl)-1,7-naphthyridines
US-2020383991-A1 · Dec 10, 2020 · US
Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
US-2020299269-A1 · Sep 24, 2020 · US
2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
US-2020289509-A1 · Sep 17, 2020 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Bayer Pharma AG | 48 |
| Bayer Ag | 23 |
| Deutsches Krebsforsch | 19 |
| Bader Benjamin | 7 |
| Koppitz Marcus | 7 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/00 | 62 |
| A61K45/06 | 46 |
| C07D471/04 | 23 |
| A61P35/02 | 23 |
| A61P43/00 | 22 |